Ophthalmology News
- Burned Out? Your Employer's Response May Surprise You
- 20 Best Places for Doctors to Retire: 2023
- Amgen Gets FTC Go-Ahead for $27.8 Billion Horizon Deal
- 5 Ways to Avert a Malpractice Lawsuit With EHR Techniques
- FDA Declines to OK Outlook Therapeutics' Eye Disease Drug
- Adolescent Eye Health Worse With Vape and Cigarette Use
- Even an Hour's Walk a Week Lowers Risk in Type 2 Diabetes
- Chatbots as Accurate as Ophthalmologists in Giving Advice
- Avoid 2 Eye Drop Products, FDA Advises
- Could Retinal Changes Be a Harbinger of Parkinson's?
- As MOC Debate Heats Up, Cardiology Societies Weigh In
- US FDA Approves Higher Dose Regeneron Eye Disease Drug Eylea
- Study Questions if Blue Light Blocking Glasses Really Work
- Could a Malpractice Insurer Drop You When You Need It Most?
- Primary Care Vision Testing Rates in Children Low
- Liver Transplant in CRC: Who Might Benefit?
- SpA-Related Diseases Share Gut Microbiota Dysbiosis
- ASRS 2023 Long-Term Outcomes of Pegcetacoplan for GA Show Promise
- Drug Name Confusion: List of Problem Medications Grows
- How to Keep Your Practice Profitable Despite Staff Shortages
- ASRS 2023 Complications From Geographic Atrophy Drug Fuel Questions
- We Asked Doctors Using AI Scribes: Just How Good Are They?
- Amgen Quarterly Revenue Rises 6%, Profit Beats Street Estimates
- Regeneron Expects FDA Decision on Higher-Dose Eylea in 2023
- Biosimilars Comparable to Aflibercept in Macular Disease